The U.S. Food and Drug Administration (FDA) has approved a new drug that could be used as a diet pill.
Wegovy is a topical medication for chronic weight management in adults who are overweight or obese. Wegovy is a higher dose of Novo’s diabetes drug semalutide.
In a study funded by the company Participants taking Wegovy lost an average of 15%, or about 34 pounds (15.3 kg). The participants continued to lose weight for 14 months before plateauing. in the comparison group receiving the simulated images. The average weight loss is about 2.5%, or less than 6 pounds.
In particular, Novo̵7;s diet pills are said to enable patients to lose weight by reducing hunger while increasing satiety.
Click here to read more about the FOX business.
The drug, which patients inject once a week, is intended for use in addition to diet and exercise, according to Novo.
A four-week supply of Wegovy, which is four injections, will cost consumers about $1,300.
This product is available with a prescription from a health care professional and is scheduled to be available at pharmacies later this month.
Get your FOX business anywhere by clicking here.
Martin Holst Lange, Executive Vice President of Development at Novo Nordisk, said: But many people who are obese struggle to gain and maintain their weight loss. Due to the physiological response that is conducive to weight loss
According to Lange, it marks a “new era in obesity treatment.”
The Associated Press contributed to this report.